Want to see MRKR full AI Analyst Report?

Marker Therapeutics (MRKR) Price & Analysis

607 Followers

MRKR Stock Chart & Stats

$1.52

$0.00(0.00%)

At close: Jul 27 4:00 PM EDT

$1.52

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.83 - $2.46

Previous Close$1.22

Volume42.26K

Average Volume (3M)69.34K

Market Cap

$20.67M

Enterprise Value$16.47

Total Cash (Recent Filing)$11.33M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.76

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.48

Shares Outstanding16,673,126

10 Day Avg. Volume95,511

30 Day Avg. Volume69,336

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.36

Price to Sales (P/S)0.00

P/FCF Ratio-1.90

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$9.00

Price Target Upside492.11% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.66

Revenue Forecast (FY)$4.18M

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetA debt-free balance sheet reduces refinancing risk, interest obligations, and exposure to lender constraints. This gives Marker greater flexibility to prioritize clinical development and limits the financial pressure that leverage could add.

Multi-Antigen T-Cell PlatformThe platform’s multi-antigen design addresses a key challenge in cancer immunotherapy: tumor immune escape. If clinical results validate this mechanism, the approach could support applications across hematologic malignancies and solid tumors.

Improving Cash-Burn TrendThe reduced cash-burn rate versus earlier periods may indicate improving spending discipline or development efficiency. Although funding needs remain substantial, continued improvement could extend the company’s operating runway and reduce financing frequency.

Bears Say

Declining RevenueDeclining revenue and the very small revenue base indicate limited commercial traction or inconsistent non-product funding. This weakens internal financing capacity and leaves Marker dependent on clinical progress, collaborations, or external capital.

Persistent Operating LossesLarge operating losses show that the current business cannot fund itself through operations. Continued unprofitability may constrain investment in the pipeline, increase dependence on financing, and amplify the consequences of delayed or unsuccessful trials.

Ongoing Capital ErosionCash losses translate directly into shareholder-capital consumption, while falling equity demonstrates cumulative erosion of the funding base. Without a material improvement in cash generation, future capital raises may remain necessary to sustain development.

Marker Therapeutics News

Marker Therapeutics: Buy Rating Reaffirmed as Pipeline Advances and Cash Runway Extends, Price Target Maintained at $8

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Marker Therapeutics, retaining the price target of...

19d ago

MRKR

Marker Therapeutics (MRKR) Q2 Earnings Cheat Sheet

Marker Therapeutics (MRKR) is scheduled to report 2nd quarter earnings on 08/19/2026. Regarding Q2 estimates, Wall Street analysts...

19d ago

MRKR

Marker Therapeutics: Buy Rating Reaffirmed with Unchanged $8 Price Target on Optimism for MT-601 Data and Pivotal Pathway

Analyst John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics and keeping the price target...

2M ago

MRKR

Buy Rating Reaffirmed on Marker Therapeutics as Clinical Milestones Near; $8 Price Target Maintained

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Marker Therapeutics, retaining the price target of...

4M ago

MRKR

MRKR Upcoming Earnings Report: What to Expect?

Marker Therapeutics (MRKR) is scheduled to report 1st quarter earnings on 05/20/2026. Regarding Q1 estimates, Wall Street analysts...

4M ago

MRKR

Marker Therapeutics Shareholders Approve Governance and Capital Changes

Marker Therapeutics ( ($MRKR) ) has shared an announcement. At its May 1, 2026 annual meeting, Marker Therapeutics’...

4M ago

MRKR

Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Marker Therapeutics and keeping the price target...

6M ago

MRKR

Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones

The latest update is out from Marker Therapeutics ( ($MRKR) ). Marker Therapeutics reported 2025 results highlighting clinical...

6M ago

MRKR

Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward

Marker Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst John Newman from...

6M ago

MRKR

Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)

Reports FY25 revenue $3.5M, consensus $3.1M. “In 2025, we continued to advance MT-601, our lead Multi-Antigen Recognizing (MAR)-T...

6M ago

MRKR

Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet

Marker Therapeutics (MRKR) is scheduled to report 4th quarter earnings on 03/12/2026. Regarding Q4 estimates, Wall Street analysts...

6M ago

MRKR

Marker announces Baylor’s TACTOPS study featured on Good Morning America

Marker Therapeutics (MRKR) announced that Baylor College of Medicine’s TACTOPS clinical study in pancreatic cancer was featured on...

7M ago

MRKR

Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

Marker Therapeutics (MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells,...

8M ago

MRKR

Marker Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $10 price...

9M ago

MRKR

MRKR FAQ

What was Marker Therapeutics Inc’s price range in the past 12 months?

Marker Therapeutics Inc lowest stock price was $0.83 and its highest was $2.46 in the past 12 months.

What is Marker Therapeutics Inc’s market cap?

Marker Therapeutics Inc’s market cap is $20.67M.

When is Marker Therapeutics Inc’s upcoming earnings report date?

Marker Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 61 days.

How were Marker Therapeutics Inc’s earnings last quarter?

Marker Therapeutics Inc released its earnings results on Aug 19, 2026. The company reported -$0.09 earnings per share for the quarter.

Is Marker Therapeutics Inc overvalued?

According to Wall Street analysts Marker Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Marker Therapeutics Inc pay dividends?

Marker Therapeutics Inc does not currently pay dividends.

What is Marker Therapeutics Inc’s EPS estimate?

Marker Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Marker Therapeutics Inc have?

Marker Therapeutics Inc has 16,673,126 shares outstanding.

What happened to Marker Therapeutics Inc’s price movement after its last earnings report?

Marker Therapeutics Inc reported an EPS of -$0.09 in its last earnings report. Following the earnings report the stock price went up 12.174%.

Which hedge fund is a major shareholder of Marker Therapeutics Inc?

Currently, no hedge funds are holding shares in MRKR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Marker Therapeutics Inc

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

Marker Therapeutics (MRKR) Earnings & Revenues

Historic Earnings Reports

MRKR Stock 12 Month Forecast

Average Price Target

$9.00

▲(492.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.3,1.9692307692307693,2.6384615384615384,3.3076923076923075,3.976923076923077,4.646153846153846,5.315384615384615,5.984615384615384,6.653846153846153,7.323076923076923,7.9923076923076914,8.661538461538461,9.330769230769231,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.3,1.8923076923076922,2.4846153846153847,3.0769230769230766,3.6692307692307695,4.2615384615384615,4.8538461538461535,5.446153846153846,6.038461538461538,6.63076923076923,7.223076923076923,7.815384615384615,8.407692307692308,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.3,1.8153846153846156,2.330769230769231,2.8461538461538467,3.361538461538462,3.8769230769230774,4.392307692307693,4.907692307692308,5.423076923076923,5.938461538461539,6.453846153846154,6.969230769230769,7.484615384615386,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.894,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.908,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.987,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >